DOCSLIB.ORG

Results of Effectiveness Trials of PRO 2000 Gel: Lessons for Future Microbicide Trials Editorial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Results of Effectiveness Trials of PRO 2000 Gel: Lessons for Future Microbicide Trials Editorial For reprint orders, please contact: [email protected] Editorial Results of effectiveness trials of PRO Microbiology Future 2000 gel: lessons for future microbicide trials “Despite numerous scientific, ethical and methodological challenges, microbicides provide real potential to influence the course of the HIV epidemic as they could fill an important gap for women-initiated prevention methods.” Salim S Abdool Karim Centre for the AIDS Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Private Bag X7, Congella 4013, South Africa n Tel.: +27 312 604 550 n Fax: +27 312 604 549 n [email protected] In sub-Saharan Africa there is a disproportionate interpreted as being consistent with this outcome burden of HIV in young women [1]. Microbicides since the 95% confidence intervals of the risk are products that can be applied to the vagina or ratios for both trials included zero effect. In this rectum with the intention of reducing the acqui- case, the point estimate of 5% increase in HIV sition of sexually transmitted infections, includ- incidence observed in the 0.5% PRO 2000 group ing HIV, in women. If proven to be effective at of the MDP 301 trial and the point estimate of reducing incident HIV infections, microbicides 30% reduction in HIV incidence observed in could fill an important HIV prevention gap, the 0.5% PRO 2000 group of the HPTN 035 especially for those women who are unable to trial is variability due purely to chance. While successfully negotiate mutual monogamy or con- the observed effect in the HPTN 035 trial is suf- dom use. Microbicides have the potential to alter ficiently distant from zero effect to suggest that the trajectory of the HIV epidemic in southern PRO 2000 may have some benefit, the p-value of Africa [2]. 0.10 meant that there was still an unacceptably To date, every effectiveness trial of candidate high likelihood that PRO 2000 is not effective microbicides has shown no impact on HIV at all. acquisition [3–8]. Indeed, trials of two products, In scenario two, PRO 2000 has a moderate COL-1492 [7] and cellulose sulfate [8], showed protective effect against HIV infection. A moder- trends toward increased risk of HIV infection. ate effect of up to 18% protection is not inconsis- The recently completed HIV Prevention Trials tent with the results of the two trials as this level Network (HPTN) 035 trial of 0.5% PRO of protection is within the upper bounds of the 2000 gel demonstrated a modest 30% reduc- 95% confidence intervals of the risk ratios from tion in HIV incidence in a four-arm study both studies. “Microbicides have the of 3099 women with 87 HIV infections in In scenario three, PRO 2000 has a substan- potential to alter the the PRO 2000 and placebo arms of this trial tial protective effect against HIV infection of, trajectory of the (risk ratio: 0.70) [9]. However, this effect on say, 55%. In this scenario, both trials may have HIV epidemic in HIV infection was not statistically significant produced underestimates of the ‘true’ effect. The southern Africa.” (p = 0.1). Subsequent findings from the almost upper bounds of the 95% confidence intervals of threefold larger Microbicide Development the risk ratios from both trials exclude this level Program (MDP) 301 trial, which had 0.5% of effect. While this scenario is unlikely, if it did PRO 2000 and placebo groups comprising 6268 occur, the underestimate would be most likely women with 253 HIV infections, showed that due to suboptimal adherence. Inadequate adher- 0.5% PRO 2000 had no protective effect against ence, especially in relation to exposure to HIV, is HIV infection (risk ratio: 1.05) [101]. one of the most serious threats that could under- mine a microbicide trial’s ability to demonstrate How should the different outcomes from an accurate level of efficacy of the product[10] . In these two trials be interpreted? microbicide trials, the effectiveness of a product There are three scenarios worthy of exploration. is dependent on both the efficacy of the product In scenario one, where PRO 2000 has no protec- and the participants’ willingness and ability to use part of tive effect against HIV infection, both the MDP the product as instructed. For example, trials with 301 trial and HPTN 035 trial results could be only 50% adherence will be able to demonstrate, 10.2217/FMB.10.29 © 2010 Future Medicine Ltd Future Microbiol. (2010) 5(4), 527–529 ISSN 1746-0913 527 Editorial Abdool Karim at most, half the true efficacy of a short-acting Despite numerous scientific, ethical and meth- product such as PRO 2000. Measuring adherence odological challenges, microbicides provide real is also challenging and although current clinical potential to influence the course of the HIV trials all include some form of assessment of prod- epidemic as they could fill an important gap for uct use, measures such as self-reported behavior women-initiated prevention methods. The joint can sometimes be unreliable. results of the HPTN 035 and MDP 301 trials Each of these scenarios provides a perspective have closed a chapter in microbicide development on how the results of the HPTN 035 and MDP by being the last studies on polymers as candidate 301 trials can be interpreted. Taken together, microbicides. Attention is now firmly focused on the results of the HPTN 035 and MDP 301 tri- antiretroviral agents for topical use as candidate als suggest that, although safe, 0.5% PRO 2000 microbicides with results on tenofovir gel due for gel may have little or no effect on reducing a release in mid 2010. woman’s risk of HIV infection during typical Questions that remain to be answered include: use and that this product is not worth pursuing n When an effective microbicide is found, what further as a potential microbicide. This outcome data will be needed to address the main obsta- was particularly disappointing as 0.5% PRO cles to widespread use; for example, safety in 2000 has potent activity against HIV in vitro pregnancy, long-term safety, safety in very [11–13] and in animal models for vaginal HIV high-frequency use, approaches to increase “...the results of the transmission [14,15]. HPTN 035 and MDP 301 over-the-counter access to the product, messag- trials suggest that, ing to promote uptake and disposable, What lessons can be learnt for future low-cost applicators? although safe, 0.5% PRO microbicides trials? 2000 gel may have little or First, these results raise a question about the n What are the most appropriate correlates no effect on reducing a usefulness of animal models that showed PRO of protection? woman’s risk of 2000 had a protective effect. Second, these n Which formulation of microbicides will be HIV infection...” results highlight the fundamental challenges most acceptable (e.g., gel, vaginal ring or film)? faced in determining which products warrant proceeding into human efficacy trials in the n How should a microbicide product be absence of a surrogate marker of protection. formulated to promote adherence? Third, adherence and measurement thereof is The interpretation of these upcoming results fundamentally important in microbicide trials on tenofovir gel will benefit enormously from the in order to exclude scenario three. Studies assess- lessons learnt from the HPTN 035 and MDP ing new formulations, such as vaginal rings, to 301 trials. improve adherence are needed. Fourth, both trials achieved their objective; the HPTN 035 Financial & competing interests disclosure study as a screening Phase IIb trial and the SS Abdool Karim is Protocol Chair of the HPTN 035 MDP 301 study as a Phase III trial have together trial which was supported by the NIH (grant # addressed the question of whether PRO 2000 is U01AI46749 and U01AI068633) and Co-Principal effective in preventing HIV infection following Investigator of the CAPRISA 004 trial of tenofovir gel, typical use. Finally, as much as we need a series which was supported by United States Agency for of human studies looking at effectiveness of International Development (# GPO-A-00-05-00022- products, we also need to build into these stud- 00, contract # 132119) and LIFElab, a South African ies a program of basic science research to iden- government biotechnology agency. The author has no tify potential surrogate markers of protection. other relevant affiliations or financial involvement Without a validated criterion to decide whether with any organization or entity with a financial interest a product should proceed, the microbicides in or financial conflict with the subject matter or mate- field is hamstrung with doing either relatively rials discussed in the manuscript apart from those large expensive screening trials or proceeding disclosed. straight to even larger and often substantially No writing assistance was utilized in the production more expensive Phase III trials. of this manuscript. Bibliography Abdool Karim Q (Eds). Cambridge microbicide’s sexually transmitted University Press, Cape Town, South Africa, infection efficacy may contribute to the 1. Abdool Karim Q: Heterosexual transmission 243–461 (2005). HIV effectiveness measured in of HIV – the importance of a gendered 2. Vickerman P, Foss A, Watts C: Using Phase 3 microbicide trials. J. Acquir. perspective in HIV prevention. In: HIV/AIDS modeling to explore the degree to which a Immune Defic. Syndr. 48(4), 460–467 in South Africa. Abdool Karim SS, (2008). 528 Future Microbiol. (2010) 5(4) future science group Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials Editorial 3. Feldblum PJ, Adeiga A, Bakare R et al.: for the prevention of HIV infection in 15. Weber J, Nunn A, O’Connor T et al.: SAVVY vaginal gel (C31G) for prevention of women: results of the HPTN 035 trial.
Load more

Recommended publications
  • Genital Tenofovir Concentrations Correlate with Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness
    BASIC AND TRANSLATIONAL SCIENCE Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness Angela D. M. Kashuba, BScPhm, PharmD, DABCP,*† Tanuja N. Gengiah, MClinPharm, PhD, MS(Epi),‡ Lise Werner, MSc,‡ Kuo-Hsiung Yang, PharmD,*† Nicole R. White, BS,*† Quarraisha A. Karim, PhD,‡§ and Salim S. Abdool Karim, MBChB, PhD‡§ plasma, and 23 paired cervical and vaginal tissue samples were Objective: The CAPRISA 004 trial showed that coitally dosed assayed by validated methods for tenofovir and tenofovir diphos- tenofovir 1% gel reduced HIV acquisition by 39% overall and 54% phate (tenofovir-DP) detection. when used consistently. The objective of this analysis was to ascertain its pharmacokinetic–pharmacodynamic relationship to pro- Results: Tenofovir was detected in the genital tract in 8 (23.5%) tect against HIV acquisition. cases and 119 (39.4%) controls (P = 0.076). Among those with detectable genital tract tenofovir, the median CVF concentrations Design: Genital and systemic tenofovir concentrations in 34 women were 97% lower in cases compared with controls, 476 versus who acquired HIV (cases) were compared with 302 randomly 13,821 ng/mL (P = 0.107). A total of 14.7% (5/34) of cases and selected women who remained HIV uninfected (controls) during 32.8% (99/302) of controls were found to have tenofovir CVF fl the CAPRISA 004 trial. In total, 336 cervicovaginal uid (CVF), 55 concentrations above 100 ng/mL [odds ratio (OR): 0.35, P = 0.037]. At a higher threshold, 8.8% (3/34) of cases and 26.2% (79/302) of controls were found to have tenofovir CVF concen- Received for publication December 19, 2014; accepted March 16, 2015.
    [Show full text]
  • CONTACT: Lisa Rossi +1- 412- 916-3315 (Mobile) [email protected]
    CONTACT: Lisa Rossi +1- 412- 916-3315 (mobile) [email protected] FOR IMMEDIATE RELEASE Results of CAPRISA 004 a turning point for HIV prevention, say MTN researchers conducting VOICE Tenofovir gel used before and after sex reduced HIV by 39 percent, raises bar for VOICE Study testing daily gel use and ARVs for preventing HIV in women VIENNA, July 19 – Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science. CAPRISA 004 involved 889 women from Durban and a nearby rural community in South Africa, where women are at especially high risk of acquiring HIV through sexual intercourse. Women were randomly assigned to one of two study groups – tenofovir gel or placebo gel with no active ingredient –and instructed to use the study product in a regimen timed before and after sex. At the end of the study, there were 39 percent fewer HIV infections among women who used tenofovir gel before and after sex than among those who used the placebo gel. The study was conducted by the Centre for the AIDS Programme of Research in South Africa (CAPRISA). “This study has established proof of concept that a vaginal microbicide containing an ARV can protect women from HIV. This is an incredibly important achievement for which the CAPRISA team is to be congratulated.
    [Show full text]
  • Next Steps 1% Tenofovir Gel
    DRAFT Next steps 1% Tenofovir Gel Meeting report Johannesburg, South Africa 25–26 August 2010 Department of Reproductive Health and Research Next Steps with 1% Tenofovir Gel Meeting Report Johannesburg, South Africa 25‐26 August 2010 23 November 2010 Next Steps with 1% Tenofovir Gel WHO/UNAIDS Meeting Report 13 January 2011 ii Next Steps with 1% Tenofovir Gel WHO/UNAIDS Meeting Report 13 January 2011 Executive Summary The results of the CAPRISA 004 trial, released in July 2010, showed that 1% tenofovir gel reduced the risk of HIV infection in women by 39% compared with placebo, and by 54% in the women who reported more consistent gel use. These results were historic. After nearly two decades of research,s thi was the first clinical trial to show that a vaginal microbicide could provide a safe and effective way to prevent sexual transmission of HIV. The gel also provided a 51% protective effect against herpes simplex virus type 2 infection (HSV‐2). The announcement raised questions about the most appropriate next steps: making the gel available to women at risk based on this single trial; planning and implementing additional trials to confirm the results; or waiting for the results of the VOICE (Vaginal and Oral Interventions to Control the Epidemic) trial, another trial of 1% tenofovir gel using a different dosing strategy. To identify priority next steps, WHO and UNAIDS convened a meeting on 25‐26 August 2010 that drew together more than 80 diverse stakeholders from a range of countries. The meeting, hosted by the South African Department
    [Show full text]
  • Px Wire: on HIV Prevention Research Volume 4 | No
    A Quarterly Update Px Wire: on HIV Prevention Research Volume 4 | No. 1 January–March 2011 AVAC’s Take Proof-of-Concept Trial Results (2009-2010) Effect size (CI) In just over a year, three large-scale trials provided evidence AIDS Vaccine 31% (1; 51) of efficacy for long-sought biomedical prevention strategies: (RV144, prime-boost) a vaccine (a prime-boost evaluated in the RV144 trial), a Microbicide 39% (6; 60) microbicide (1% tenofovir gel evaluated in the CAPRISA 004 (CAPRISA 004, trial) and an oral pre-exposure prophylaxis (PrEP) strategy tenofovir gel) (daily TDF/FTC evaluated in the iPrEx trial). At first glance, PrEP 44% (15; 63) the outcomes appear similar—each had a point estimate of (iPrEx, TDF/FTC) efficacy between 30 and 44 percent. But scratch the surface 0% 10 20 30 40 50 60 70 80 90 100% and it becomes clear that the interpretations and ramifications Efficacy for each of these trials are quite distinct. In this exciting time, advocates’ voices are needed to guide next steps. This is why we’ve chosen to start 2011 with a review of what’s happened and what lies ahead for each strategy. vaccine candidate to learn more about immune responses over the long term. AIDS Vaccines • The RV144 trial partners are developing a follow-up trial It’s been 15 months since the team behind the in Thailand that would enroll MSM and could serve as 16,400-person Thai prime-boost trial (also known as a confirmatory trial for the initial RV144 finding in a RV144) announced that a strategy, comprised of ALVAC-HIV higher-incidence cohort.
    [Show full text]
  • Microbicides and Their Potential As a Catalyst for Multipurpose Sexual and Reproductive Health Technologies
    DOI: 10.1111/1471-0528.12843 Review article www.bjog.org Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies Q Abdool Karim,a,b C Baxter,a S Abdool Karima,b a CAPRISA—Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa b Department of Epidemiology, Columbia University, New York, NY, USA Correspondence: Q Abdool Karim, CAPRISA 2nd Floor, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Private Bag X 7, Congella, 4013, Durban, South Africa. Email [email protected] Accepted 13 March 2014. There is an urgent need for technologies to prevent sexual multipurpose products that address challenges of adherence and acquisition of HIV infection in young women in sub-Saharan meet the sexual and reproductive health needs of men and Africa. After two decades of 11 pivotal trials of seven products, women, including preventing HIV infection, are underway. anti-retroviral-based topical microbicides are showing promise. Building on the CAPRISA 004 trial findings, several trials of new Keywords HIV prevention, microbicide, tenofovir gel, women. anti-viral agents, novel delivery mechanisms and combination/ Please cite this paper as: Abdool Karim Q, Baxter C, Abdool Karim S. Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies. BJOG 2014; 121 (Suppl. 5): 53–61. 1 What are microbicides? reduced AIDS-related mortality between 2005 and 2012. Anti-retroviral therapy has also been shown to have the Microbicides are vaginally or rectally applied chemical added benefit of preventing transmission of HIV in discor- products designed to prevent the sexual acquisition of HIV.
    [Show full text]
  • Questions and Answers CAPRISA 004 TENOFOVIR GEL TRIAL
    PAGE 1 Questions and Answers CAPRISA 004 TENOFOVIR GEL TRIAL A randomized, controlled trial to assess the safety and effectiveness of a vaginal microbicide, tenofovir gel, for the prevention of HIV infection among women in South Africa Why did CAPRISA conduct a trial of tenofovir gel for HIV prevention? The CAPRISA 004 study was conducted to establish whether the vaginal use of tenofovir gel is safe and whether it can prevent male‐to‐female sexual transmission of HIV. Specifically, researchers conducted CAPRISA 004 to evaluate the safety and effectiveness of tenofovir in comparison to a placebo gel (a matched gel with no active ingredient) in sexually active women at risk for human immunodeficiency virus (HIV) infection in South Africa. Who conducted this trial? CAPRISA 004 was conducted by a team of South African and American researchers with funds provided by the United States Agency for International Development (USAID) and South Africa’s Technology Innovation Agency (TIA), with product supplied by CONRAD, and with collaborating support from FHI. The principal investigators (study leaders) are Professor Quarraisha Abdool Karim and Professor Salim S. Abdool Karim. When did the trial begin and how was it designed? CAPRISA 004 was a Phase IIb, two‐group, double‐blind, randomized, controlled trial to assess the safety and effectiveness of 1% tenofovir gel, a candidate vaginal microbicide, in 889 sexually active HIV‐ uninfected urban and rural women at risk for HIV infection in South Africa. After undergoing the informed‐consent process, each participant was randomly assigned to one of the two study groups: tenofovir gel or placebo gel.
    [Show full text]
  • Microbicide Overview
    Microbicide Overview HIV/AIDS ranks among the world’s most devastating diseases because it has spread rapidly and mainly affects young people in their most productive years. More than 33 million people worldwide are living with HIV/AIDS, and 25 million already have died from AIDS (UNAIDS/WHO, November 2009). Each day, about 7,000 more women, men and children become infected with HIV, the virus that causes AIDS. More than 15 million children are without families and homes because of the epidemic, more than 12 million of whom are in sub-Saharan Africa (UNAIDS/WHO, July 2008). Women bear a particularly high burden of the epidemic as primary caregivers for the ill and because of their heightened risk of infection due to biological, economic and social vulnerabilities. Based on the latest comprehensive WHO data, HIV/AIDS is the leading cause of death globally in women 15-44 years of age, particularly in sub-Saharan Africa where the epidemic has hit hardest. Heterosexual sex is the primary mode by which HIV spreads in developing countries. Although a range of prevention strategies exists, they are not enough to stop the spread of HIV — particularly among women. Many women may be unable to persuade their male partners to use condoms or remain faithful. Abstinence is not an option for women who are married, who want children or who are at risk of sexual violence. This is why new prevention strategies that women can use themselves are urgently needed. One such strategy would be microbicides — medical products being developed to protect healthy people from becoming infected with HIV during sex.
    [Show full text]
  • Background and Rationale
    Phase III Sister Studies of a Microbicide Ring to Prevent HIV: The Ring Study and ASPIRE Summary The Ring Study and ASPIRE are the first large-scale clinical trials to assess whether a vaginal ring containing the antiretroviral (ARV) drug dapivirine can safely and effectively protect against the sexual transmission of HIV when used by women for a month at a time. As sister studies, they represent a major step toward a promising female-controlled HIV prevention method that could potentially provide women with discreet, long-acting protection. Vaginal rings are flexible products that fit comfortably inside the vagina and provide sustained delivery of drugs over a period of time. Vaginal rings are already used in many countries to deliver hormonal contraception. IPM’s dapivirine ring adapts that medical technology as a way to fight HIV. The Ring Study is being conducted by the International Partnership for Microbicides (IPM), which developed the dapivirine ring. ASPIRE – A Study to Prevent Infection with a Ring for Extended Use – is being conducted by the Microbicide Trials Network (MTN) and is funded by the National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health, which are part of the U.S. National Institutes of Health. More than 5,000 women from southern and East Africa will take part in the two studies, which are being conducted in parallel. The dapivirine ring is the first ARV-based product to enter efficacy testing that is intended for monthly use and the first involving an ARV other than tenofovir or a tenofovir combination.
    [Show full text]
  • Preventive Technologies Agreement (PTA) Advancing the Science of HIV Prevention the U.S
    END-OF-PROJECT REPORT Preventive Technologies Agreement (PTA) Advancing the Science of HIV Prevention The U.S. Agency for International Development (USAID) awarded the Preventive Technologies Agreement (PTA) to FHI 360 in 2009. The PTA End-of-Project Report: Advancing the Science of HIV Prevention provides an overview of the results and accomplishments of the five-year PTA project. For additional information on particular activities or technical areas undertaken by the PTA, please see the PTA website at http://www. fhi360.org/projects/preventive-technologies-agreement-pta © FHI 360, 2014 Photo credits: cover and page 2, Jessica Scranton cover and page 16, Leigh Wynne/FHI 360 page 4, Sarah Mullins/FHI 360 cover and page 17, Jessica Scranton cover and page 5, Natasha Mack/FHI 360 page 18, Ian Taylor page 7, Natasha Mack/FHI 360 cover and page 22, Sarah Mullins/FHI 360 cover and page 9, Jessica Scranton page 23, James Kilonzo, Courtesy of Photoshare page 10, Michele Lanham/FHI 360 page 24, Jessica Scranton page 11, Natalie Eley/FHI 360 cover and page 25, Kim Best cover and page 12, Michele Lanham/FHI 360 page 26, Kim Best page 15, Jessica Scranton page 27, Jessica Scranton Table of Contents Introduction 2 HIV Prevention for Women Integration of HIV Prevention and Reproductive Health Technologies Research Support, Field Support, and Product Quality and Compliance HIV Prevention Clinical Trials 5 CAPRISA 004 CAPRISA 104 and 106 FEM-PrEP Support for HIV Prevention Research 9 Science Facilitation Good Communication Practices Assuring Stakeholder
    [Show full text]
  • CAPRISA 10 Year Brochure
    CELEBRATING 10 YEARS OF WORLD CLASS HIV, AIDS AND TB RESEARCH Contents 02 CAPRISA Overview 04 Message From Dr Aaron Motsoaledi, Minister of Health 05 Message From Mr Derek Hanekom, Minister of Science and Technology Messages from the CAPRISA Boards 06 Dr Catherine Hankins, Chairperson, Scientific Advisory Board 07 Professor Ahmed Bawa, Chairperson, Board of Control 08 Introduction by the CAPRISA Director Professor Salim S Abdool Karim, Director, CAPRISA 09 Setting the research agenda 10 Our accomplishments 16 Our partnership philosophy 17 Building capacity 18 Leadership 19 CAPRISA’s Structure 21 Acknowledgements Contact details CAPRISA is a multi-institution programme established in 2002 under the National Institutes for Health (NIH)-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions: University of KwaZulu-Natal University of Cape Town University of Western Cape National Institute of Communicable Diseases Columbia University in New York. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research and Policy, and the secretariat for the UNAIDS Scientific Expert Panel. The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV pathogenesis, prevention and epidemiology, as well as the links between tuberculosis and AIDS care. 02 10 Years | CAPRISA To achieve this goal, CAPRISA conducts research in four main research programmes: HIV prevention and epidemiology; microbicides; HIV pathogenesis and vaccines; and HIV and TB treatment. A fifth area of research on the prevention of mother- to-child transmission is conducted mainly with partners. Research activities at CAPRISA are assisted by eight support cores covering administration, biostatistics, data management, laboratory, community, pharmacy, bioethics and information systems.
    [Show full text]
  • Pre-Exposure Prophylaxis (Prep) by the Numbers
    The figures below show the relationship between PrEP efficacy and adherence, and the status of regulatory action on PrEP worldwide. Different countries are moving at Pre-Exposure Prophylaxis different speeds. Many are looking to demonstration projects—small-scale pilots that provide information on how to deliver PrEP in real-world settings. Unfortunately, the vast majority of the projects that are currently delivering PrEP are outside of sub- (PrEP) by the Numbers Saharan Africa. This despite the fact that sub-Saharan Africa is where many new HIV acquisitions, particularly via sexual transmission, are taking place today. Now is the time to take regulatory action and to move ahead with demonstration projects linked Efficacy, regulatory approval and more to plans for scale-up. Other formulations of ARV-based prevention are also being evaluated and could provide additional options in the future. PrEP Works if You Take It — Effectiveness and Adherence in Trials of Oral and Topical Tenofovir-Based Prevention 100 Trials of oral and topical CAPRISA 004 (tenofovir gel, BAT-24 dosing) tenofovir-based PrEP show 80 iPrEx that these strategies reduce 60 TDF2 risk of HIV infection if they ) 40 Partners PrEP (TDF) are used correctly and ss (% 20 consistently. Higher adherence ene Partners PrEP (TDV/FTC) iv ect is directly linked to greater f 0 FEM-PrEP levels of protection. Ef -20 VOICE (TDF) VOICE (TDF/FTC) Calculations based on -40 VOICE (tenofovir gel, analyses involving a subset -60 daily dosing) of total trial participants. 10 20 30 40 50 60 70 80 90 Percentage of participants' samples that had detectable drug levels Pearson correlation = 0.86, p=0.003 Source: Salim S.
    [Show full text]
  • Arvs for Prevention in At-Risk Populations: Microbicides Treatment As Prevention in Africa Meeting Botswana, April 30 – May 3, 2014
    ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 – May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research): University of KwaZulu-Natal Professor in Clinical Epidemiology, Columbia University Adjunct Professor of Medicine, Cornell University Associate: Ragon Institute of MGH, MIT and Harvard HIV prevalence in school boys & girls in rural South Africa (Grades 9 & 10) HIV Prevalence (Oct/Nov 2010) Age % (95% Confidence Interval) Group Male Female 14 1.0 (0.0 – 3.0) 15-16 1.4 (0.4 – 2.4) 17-18 1.2 (0.2 – 2.2) 19-20 1.1 (0.0 – 2.7) RHIVA collaboration with MiET Africa and DoE with funding from the Royal Netherlands Embassy HIV prevalence in school boys & girls in rural South Africa (Grades 9 & 10) HIV Prevalence (Oct/Nov 2010) Age % (95% Confidence Interval) Group Male Female 14 1.0 (0.0 – 3.0) 2.2 (0.3 – 4.0) 15-16 1.4 (0.4 – 2.4) 3.6 (2.2 – 5.0) 17-18 1.2 (0.2 – 2.2) 7.9 (5.0 - 11.0) 19-20 1.1 (0.0 – 2.7) 16.0 (9.2 – 22.0) RHIVA collaboration with MiET Africa and DoE with funding from the Royal Netherlands Embassy HIV prevalence in young pregnant women in rural Vulindlela, South Africa (2009-2012) Age Group HIV Prevalence (Years) (N=1029) ≤16 8.4 17-18 18.6 19-20 25.4 21-22 32.8 23-24 44.8 High rates of HIV among the key populations of young women in Africa HIV in 15–24 year men and women (2008–2011) Young women have up to 8 times more HIV than men Zimbabwe Source: Adapted from UNAIDS 2012 HIV risk in young women in Africa • Pressure to have sex
    [Show full text]